• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

UGT1A1 Gene Record

  • Summary
  • Interactions
  • Claims
  • UGT1A1 54658 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    54658
    UDP GLUCURONOSYLTRANSFERASE FAMILY 1 MEMBER A1
    UGT1A1
    BILIQTL1
    GNT1
    HUG-BR1
    UDPGT
    UDPGT 1-1
    UGT1
    UGT1A
    191740
    12530
    ENSG00000241635
    OTTHUMG00000059117
    PA420
    P22309
    12422
    UDP-glucuronosyltransferase 1-1
    2990
    NP_000454
    BE0003541

    Gene Info:

    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name UDP glucuronosyltransferases (UGT)
    GuideToPharmacology Gene Category ID 988
    (9 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    DRUGGABLE GENOME
    DRUG METABOLISM
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    An SH et al., 2015, Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves., Cardiovasc Ther
    Bhatt DK et al., 2019, Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver., Clin Pharmacol Ther
    Kobie J et al., 2019, Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies., J Clin Pharmacol
    Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
    Haas DW et al., 2014, Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes., J Antimicrob Chemother
    Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol
    Motzer RJ et al., 2013, Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms., Ann Oncol
    Yamasaki S et al., 2015, UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan., Ann Hematol
    Singer JB et al., 2007, UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia., Leukemia
    Abumiya M et al., 2014, Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia., Drug Metab Pharmacokinet
    Chen S et al., 2014, Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics., Pharmacogenomics
    Cecchin E et al., 2009, Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan., J Clin Oncol
    Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.
    Lankisch TO et al., 2008, Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk., Cancer Epidemiol Biomarkers Prev
    Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
    Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
    Kishi S et al., 2004, Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia., Blood
    Kawato Y et al., 1991, Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11., Cancer Res
    Obradovic M et al., 2008, Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer., Pharmacogenomics
    Danoff TM et al., 2004, A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia., Pharmacogenomics J
    Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk., Clin Cancer Res
    Onoue M et al., 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients., Int J Clin Oncol
    Hoskins JM et al., 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters., J Natl Cancer Inst
    Kemp DC et al., 2002, Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance., Drug Metab Dispos
    Ciotti M et al., 1999, Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus., Biochem Biophys Res Commun
    Guillemette C et al., 2000, Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene., Pharmacogenetics
    James RE et al., 2011, Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study., Cancer Prev Res (Phila)
    Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics
    Lin JP et al., 2010, Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease., Clin Chem
    Stender S et al., 2013, Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis., J Intern Med
    Lin JP et al., 2006, Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study., Circulation
    Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med
    Ekblom K et al., 2010, Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting., Circ Cardiovasc Genet
    Bosma PJ et al., 2003, UGT1A1*28 allele and coronary heart disease: the Rotterdam Study., Clin Chem
    Tukey RH et al., 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease., Annu Rev Pharmacol Toxicol
    Yamamoto K et al., 1998, Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II., Biochim Biophys Acta
    Strassburg CP, 2008, Pharmacogenetics of Gilbert's syndrome., Pharmacogenomics
    Monaghan G et al., 1999, Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn., J Pediatr
    Strassburg CP et al., 2000, Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine., J Biol Chem
    Servedio V et al., 2005, Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation., Hum Mutat
    Strassburg CP et al., 1998, Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium., Mol Pharmacol
    Iolascon A et al., 1999, (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome., Haematologica
    Arias IM et al., 1969, Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity., Am J Med
    Fang JL et al., 2002, Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes., Cancer Res
    Guillemette C et al., 2001, Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels., Cancer Epidemiol Biomarkers Prev
    Adegoke OJ et al., 2004, Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer., Breast Cancer Res Treat
    Boyd MA et al., 2006, Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir., Pharmacogenet Genomics
    Pett S et al., 1987, Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation., Mol Aspects Med
    Sneitz N et al., 2010, Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants., Hum Mutat
    Williams JA et al., 2002, Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes., Drug Metab Dispos
    Sai K et al., 2004, UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer., Clin Pharmacol Ther
    Akaba K et al., 1998, Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese., Biochem Mol Biol Int
    Zhang D et al., 2007, Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism., Drug Metab Dispos
    Tsezou A et al., 2007, Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women., Genet Test
    Tukey RH et al., 2002, Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity., Mol Pharmacol
    Bosma PJ et al., 1994, Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man., J Biol Chem
    Bajro MH et al., 2012, Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer., Cancer Genet
    Ritter JK et al., 1991, Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells., J Biol Chem
    Guillemette C et al., 2000, Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans., Cancer Res
    Schauer R et al., 2003, Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation., J Pediatr Surg
    Kadakol A et al., 2000, Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype., Hum Mutat
    Girard H et al., 2005, UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver., Hepatology
    Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J
    Jada SR et al., 2007, Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci
    Hall D et al., 1999, Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates., Pharmacogenetics
    Toffoli G et al., 2006, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer., J Clin Oncol
    Rotger M et al., 2005, Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia., J Infect Dis
    Ando Y et al., 2000, Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis., Cancer Res
    Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis., Eur J Cancer
    Rouits E et al., 2004, Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients., Clin Cancer Res
    Zhang D et al., 2005, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation., Drug Metab Dispos
    Takano M et al., 2009, Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study., Oncology
    Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
    Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
    Innocenti F et al., 2004, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan., J Clin Oncol
    Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
    Urawa N et al., 2006, Linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms., Oncol Rep
    Turatti L et al., 2012, Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil., AIDS Res Hum Retroviruses
    Zientek MA et al., 2016, In Vitro Kinetic Characterization of Axitinib Metabolism., Drug Metab Dispos
    Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
    Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
    Takekuma Y et al., 2006, Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol., J Pharm Pharm Sci
    Zhou J et al., 2011, Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors., Drug Metab Dispos
    Kim KP et al., 2015, A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI., Oncology
    Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol
    Stewart CF et al., 2007, UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan., J Clin Oncol
    Mbatchi LC et al., 2016, Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients., Clin Pharmacokinet
    de Jong FA et al., 2007, Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein., Clin Pharmacol Ther
    Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
    Iyer L et al., 2002, UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity., Pharmacogenomics J
    de Jong FA et al., 2006, Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study., Oncologist
    Erickson-Ridout KK et al., 2012, Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms., Pharmacogenet Genomics
    Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
  • BILIRUBIN   UGT1A1

    Interaction Score: 13.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21813404 10353933 20693308 22805420 17000907 7565971 20562445 12816916 10836148 9630669 18518849 10190918 10748067 15712364 9765507 10091406 4897277 11929814 11401924 15111762 16609363 3306242 19830808 12386134 15179405 9784835 17898154 17949292 12181419 8027054 22559977 1898728 10706110 12891498 11013440 15986396


    Sources:
    PharmGKB

  • INDINAVIR   UGT1A1

    Interaction Score: 3.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10353933 7565971 17627617 9630669 17058217 10591539 16809730 16170755 11156391 20562211 20335017 19390945 15297419 17728214 16609363 16118329 9784835 19299905 12181419 20504240 15709193 15007088 16456808 16969497 22050734


    Sources:
    PharmGKB

  • TRANILAST   UGT1A1

    Interaction Score: 2.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 17728214 12019197 10381366 11037804


    Sources:
    PharmGKB

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   UGT1A1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25427841 16636344 19364970 19852077 17577039 27116457 18349289 17627617 12181437 17058217 17185998 12969965 1651156 18466101 14647407 20562211 19390945 17728214 12019197 18221820 11990381 15179405 10381366 16951398 15007088 11037804


    Sources:
    PharmGKB

  • LETERMOVIR   UGT1A1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31022310


    Sources:
    PharmGKB

  • DOLUTEGRAVIR   UGT1A1

    Interaction Score: 0.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24329186


    Sources:
    FDA PharmGKB

  • RALOXIFENE   UGT1A1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 17728214 12019197 10381366 11037804


    Sources:
    PharmGKB

  • RALTEGRAVIR   UGT1A1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • ARFORMOTEROL   UGT1A1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • INDACATEROL   UGT1A1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • NILOTINIB   UGT1A1

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family BCR-ABL inhibitor 2nd gen
    Alteration UGT1A1:.
    Alteration UGT1A1:G71R,P229Q

    PMIDs:
    17611564 24898899


    Sources:
    FDA PharmGKB CGI

  • ETOPOSIDE   UGT1A1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 25055799 17728214 12019197 10381366 11037804


    Sources:
    PharmGKB

  • BELINOSTAT   UGT1A1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26313268


    Sources:
    FDA CIViC

  • FEBUXOSTAT   UGT1A1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • ETHINYL ESTRADIOL   UGT1A1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21030469


    Sources:
    DTC

  • AXITINIB   UGT1A1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26512042


    Sources:
    PharmGKB

  • LOSARTAN   UGT1A1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EFAVIRENZ   UGT1A1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24729586


    Sources:
    PharmGKB

  • CARVEDILOL   UGT1A1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20643254 16849011


    Sources:
    PharmGKB

  • BINIMETINIB   UGT1A1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • PAZOPANIB   UGT1A1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family VEGFR inhibitor
    Alteration UGT1A1:.

    PMIDs:
    24107802


    Sources:
    FDA PharmGKB CGI

  • DAIDZEIN   UGT1A1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21030469


    Sources:
    DTC

  • WARFARIN   UGT1A1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26223945 29737521


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • RITONAVIR   UGT1A1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Details of Interaction Both inhibitor and substrate
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • FLUVASTATIN   UGT1A1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   UGT1A1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration UGT1A1:G71R,P229Q
    Alteration UGT1A1:.
    Drug family TOPO1 inhibitor

    PMIDs:
    None found


    Sources:
    FDA CGI

  • RUCAPARIB   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29955115


    Sources:
    PharmGKB

  • OLANZAPINE   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • CARBOPLATIN   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25055799


    Sources:
    PharmGKB

  • CLOZAPINE   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22565219


    Sources:
    PharmGKB

  • DEXAMETHASONE   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25055799


    Sources:
    PharmGKB

  • LOVASTATIN   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ERLOTINIB   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   UGT1A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FOSTAMATINIB   UGT1A1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    26516587


    Sources:
    DrugBank

  • Ensembl: ENSG00000241635

    • Version: 101_38

    Alternate Names:
    UGT1A1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • GuideToPharmacology: 54658

    • Version: 29-September-2020

    Alternate Names:
    12530 HUGO Gene ID
    12530 HUGO Gene Symbol
    UDP glucuronosyltransferase family 1 member A1 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name UDP glucuronosyltransferases (UGT)
    GuideToPharmacology Gene Category ID 988

    Gene Categories:
    ENZYME

    Publications:

  • PharmGKB: UGT1A1

    • Version: 18-August-2020

    Alternate Names:
    PA420 PharmGKB ID

    Gene Info:

    Publications:
    Haas DW et al., 2014, Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes., J Antimicrob Chemother
    Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J
    Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol

  • CIViC: UGT1A1

    • Version: 14-September-2020

    Alternate Names:
    54658 Entrez Gene ID
    12422 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol

  • DrugBank: BE0003541

    • Version: 5.1.7

    Alternate Names:
    UGT1A1 DrugBank Gene Name
    P22309 UniProt Accession
    54658 Entrez Gene Id

    Gene Info:

    Publications:
    Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

  • DTC: UGT1A1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Zhou J et al., 2011, Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors., Drug Metab Dispos

  • HingoraniCasas: ENSG00000241635

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000241635 Gene Symbol
    UGT1A1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HumanProteinAtlas: UGT1A1

    • Version: 19.3

    Alternate Names:
    ENSG00000241635 Ensembl Gene ID
    GNT1 Human Protein Atlas Gene Synonym
    UGT1 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • Pharos: UGT1A1

    • Version: 03-September-2020

    Alternate Names:
    UDP-glucuronosyltransferase 1-1 Gene Name
    P22309 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • GO: UGT1A1

    • Version: 05-September-2020

    Alternate Names:
    GNT1 GO Gene Synonym
    UGT1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, DRUG METABOLISM

    Publications:

  • Tempus: UGT1A1

    • Version: 11-November-2018

    Alternate Names:
    UGT1A1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CGI: UGT1A1

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:

  • FDA: UGT1A1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21